Drug Information

Drug General Information
Drug ID
D01OIL
Former ID
DAP001225
Drug Name
Gadobenate Dimeglumine
Synonyms
Hydron; Multihance; Gadobenate Dimeglumine [USAN]; Gadobenic acid; Gadobenic acid dimeglumine salt; Meglumine gadobenate; Multihance Multipack; B 1903617; E-7155; Gadobenate dimeglumine (USAN); Gd-BOPTA; Meglumine gadobenate (JAN); Multihance (TN); B-19036/7; Gadolinium(3+); Gd-Bopta/dimeg; Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2); 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]-3-phenylmethoxypropanoate; 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; D-Glucitol, 1-deoxy-1-(methylamino)-, (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8), O(sup 11),O(sup 13)-gadolinate(2-) (2:1); Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8),O(sup 11),O(sup 13))-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)
Drug Type
Small molecular drug
Indication Visualizing lesions with abnormal blood brain barrier [ICD9: 437.9; ICD10:I67.9] Approved [527466], [538563], [551871]
Therapeutic Class
Contrast Media
Structure
Download
2D MOL

3D MOL
Formula
C36H62GdN5O21
Canonical SMILES
CNCC(C(C(C(CO)O)O)O)O.CNCC(C(C(C(CO)O)O)O)O.C1=CC=C(C=C<br />1)COCC(C(=O)[O-])N(CCN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-<br />])CC(=O)O.[Gd+3]
InChI
1S/C22H31N3O11.2C7H17NO5.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;2*1-8-2-4(10)6(12)7(13)5(11)3-9;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);2*4-13H,2-3H2,1H3;/q;;;+3/p-3/t;2*4-,5+,6+,7+;/m.00./s1
InChIKey
OCDAWJYGVOLXGZ-VPVMAENOSA-K
CAS Number
CAS 113662-23-0
PubChem Compound ID
6918204
PubChem Substance ID
12014647, 46506805, 57371834, 75285303, 114787603, 160964086
SuperDrug ATC ID
V08CA08
Target and Pathway
Target(s) Serum albumin Target Info Binder [536789]
Pathway Interaction Database FOXA2 and FOXA3 transcription factor networks
Reactome Platelet degranulation
Recycling of bile acids and salts
HDL-mediated lipid transport
Scavenging of heme from plasma
WikiPathways Human Complement System
Binding and Uptake of Ligands by Scavenger Receptors
Lipid digestion, mobilization, and transport
Transport of vitamins, nucleosides, and related molecules
Bile acid and bile salt metabolism
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 5274662004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
Ref 538563FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021357.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 536789Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.